BA—ELISA检测人血浆异常凝血酶原用于原发性肝癌的诊断

MEASUREMENT OF HUMAN PLASMA ABNORMAL PROTHROMBIN BY BIOTIN-AVIDIN(BA) ELISA IN THE DIAGNOSIS OF HEPATOCELLULAR CARCINOMA

以钡盐吸附除去血浆凝血酶原后,用生物素—亲和素酶联免疫吸附测定法(Biotin Avidjn ELISA)检测了39例健康人,42例原发性肝细胞肝癌(HCC)患者及17例肝脏良性病变患者血浆异常凝血酶原(AP)含量,结果显示HCC患者血浆AP含量≥150ng/ml的占64.3％。20例血清甲胎蛋白(AFP)阴性患者血浆的60％AP含量≥150ng/ml。两者相结合,可使HCC诊断率提高到81％。对12例癌肿直径小于5 cmHCC患者的血浆AP含量的检测,得到类似的结果。提示血浆AP的检测,有助于提高HCC的诊断率。

After the reomval of fibrinogen and prothrombin by bentonite and barium citrate, the abnormal prothrombin (AP)that remained in human plasma was estimated by BA- ELISA in 39 healthy adults, 42 patients with primary hepatocellular carcinoma (HCC) and 17 patients with benign liver diseases. The results indicated that among the 42 HCC patients 27 patients (64.3%) showed a plasma AP level ≥150ng/ml. Among 20 patients of HCC with low AFP level (<400ng/ml) 12 (60%) showed a plasma AP level≥150ng/ml. Some of them had a tumor of diameter< 5cm. A toral of 34 HCC patients (81% in the 42 HCC cases) could be diagnosis by both AFP and AP determination. This suggests that the AP level in human plasma can be used as a marker for the diagnosis of hepatocellular carcinoma, and BA -ELISA may be considered as a useful method in assaying of AP in human plasma.